UAE: Abu Dhabi launches real-world study to assess safety of AstraZeneca’s ‘Evusheld’

UAE: Abu Dhabi launches real-world study to assess safety of AstraZeneca’s ‘Evusheld’

The data will be critical in protecting immunocompromised patients from symptomatic Covid-19

Published: Mon 29 Aug 2022, 5:38 PM Last updated: Mon 29 Aug 2022, 5:48 PM

Abu Dhabi has launched a real-world evidence (RWE) study that aims to offer critical real-world data on the safety and effectiveness of AstraZeneca’s long-acting antibody combination, Evusheld, in protecting immunocompromised patients in the UAE from symptomatic Covid-19.

The study is one of the many fruits of the Declaration of Collaboration signed last year between the Department of Health - Abu Dhabi (DoH), and AstraZeneca.

The collaboration aims to further enhance research and development in health sciences and boost innovation in the healthcare sector as part of DoH’s strategy to increase patients’ access to quality healthcare services.

The EVOLVE Real World Evidence Study, which is expected to continue till the end of 2023 with up to 1,000 participants, is a collaboration between AstraZeneca and Sheikh Khalifa Medical City (SKMC) hospital in Abu Dhabi, under the supervision of DoH.

Abu Dhabi was among the first group of cities to receive the first global shipment of AstraZeneca’s Evusheld, a long-acting antibody medication, to ensure the continuity of world-class care in the country.

The multi-country, prospective observational study will support high-risk individuals across the